Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
Research output: Contribution to journal › Journal article › Research › peer-review
Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30).
| Original language | English |
|---|---|
| Journal | European Journal of Endocrinology |
| Volume | 167 |
| Issue number | 2 |
| Pages (from-to) | 287-94 |
| Number of pages | 8 |
| ISSN | 0804-4643 |
| DOIs | |
| Publication status | Published - 2012 |
ID: 48605745